.png)
Designed for Leaders Responsible for Outcomes
6,000+ c-suite attendees controlling
$1 Trillion+ in annual spend
Know What's Possible
Genome Unveiled exists to show how these decisions can be made tomorrow, not how they are made today.
Months of Learning in Hours
Healthcare data has outpaced executive understanding. At the same time Genomics, AI, and multi-omics, are reshaping portfolios faster than leaders can synthesize. Today’s conferences fragment information into panels and PowerPoints or speak to topics far downstream from executive decision-making. The result is that executives lack a shared, intuitive mental model to make platform-level decisions.
Genome Unveiled is an immersive executive platform where leaders in pharma, biotech, and AI learn how to make better, faster decisions using real-world data, genomics, and advanced analytics. Through cinematic storytelling and curated executive experiences, it transforms complex science into actionable strategies for billion-dollar impact.
Day 1 - Frame the Decisions
Align on the models, pressures, and opportunities shaping biopharma today
Day 2 - Experience the Future
See decisions visualized at unprecedented scale
Day 3 - Inside Your Walls
Translate insight into action across your organization
See the Decisions Before You Make Them
On Day 2, experience something never seen before as complex portfolio, trial, and market dynamics are visualized at a scale never before possible, transforming abstract data into clear, actionable decision frameworks.
1 Trial Rescue scenarios in real time
Experience how clinical trials fail and how they can be saved through real-time simulation of patient drop-off, protocol breakdowns, and emerging risk signals. Genome Unveiled reveals how AI and live data can intervene mid-trial to preserve outcomes, timelines, and billions in at-risk investment.
2 Portfolio reallocation across billions
Step inside the moment where capital moves. Through immersive portfolio simulations, executives see how data, probability, and AI-driven insight reshape investment decisions across entire pipelines, revealing when to double down, when to pivot, and when to walk away.
3 Phase IV expansion pathways revealed
Unlock the hidden growth potential beyond approval. Genome Unveiled surfaces how real-world data, responder identification, and AI-driven insight expose new patient populations, indications, and markets, turning existing therapies into multi-billion-dollar expansion opportunities.
